Peter Horby | |
|---|---|
| Born | Peter William Horby |
| Alma mater | University College London (MBBS) London School of Hygiene and Tropical Medicine (PhD) |
| Scientific career | |
| Institutions | University of Oxford |
| Thesis | Avian, inter-pandemic, and pandemic influenza in Vietnam |
| Doctoral advisor | Neal Alexander |
| Website | www |
Sir Peter William Horby is a Britishphysician,epidemiologist, Moh Family Foundation Professor of Emerging Infections and Global Health, and Director of the Pandemic Sciences Institute at theUniversity of Oxford. He is the founder, and former director of the Oxford University Clinical Research Unit in Hanoi, Vietnam which was founded in 2006. In 2014, Horby established the Epidemic Research Group Oxford (ERGO). ERGO incorporates a number of international projects such as the European Commission funded PREPARE, the African coaLition for Epidemic Research, Response and Training (ALERRT), and theInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC). Since 2016, Horby has been chair and executive director of ISARIC.
Horby specialises in emerging and epidemic infectious diseases. He is the co-chief investigator of theRECOVERY Trial into drugs forCOVID-19 (the largest clinical trial of COVID-19 in the world) alongsideMartin Landray.[1][2][3] In June 2020, he gave a statement at10 Downing Street alongside the Prime Minister and Chief Scientific Adviser announcing the first positive trial results of the first life-saving COVID-19 drug,Dexamethasone.[4][5] He is the primary author on the published preliminary report.[6]
From 2020 to 2022, Horby was one of the attendees of theScientific Advisory Group for Emergencies (SAGE)[7] He is the chair of theNew and Emerging Respiratory Virus Threats Advisory Group (NERVTAG).[8][7]
He wasknighted in the2021 Birthday Honours for services to medical research[9] and he was elected aFellow of the Royal Society in 2024.[10]
| International | |
|---|---|
| National | |
| Academics | |
| Other | |
